Swedbank Ab Novavax Inc Transaction History

Swedbank Ab

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 21, 2024	BUY	$3.76 - $6.02 $20,710 - $33,158	5,508 New	5,508 $26.3 Million
Q3 2023 Dec 09, 2024	SELL	$6.81 - $9.74 $68 - $97	-10 Reduced 0.13%	7,446 $53,000
Q2 2023 Dec 09, 2024	SELL	$6.67 - $9.52 $53 - $76	-8 Reduced 0.11%	7,456 $55,000
Q1 2023 Dec 09, 2024	BUY	$5.76 - $12.48 $662 - $1,435	115 Added 1.56%	7,464 $51,000
Q3 2022 Dec 09, 2024	SELL	$18.2 - $76.12 $2,693 - $11,265	-148 Reduced 1.97%	7,349 $133,000
Q2 2022 Dec 09, 2024	SELL	$36.28 - $75.29 $1 Million - $2.09 Million	-27,697 Reduced 78.7%	7,497 $385,000
Q1 2022 Dec 09, 2024	BUY	$69.73 - $142.9 $1.07 Million - $2.2 Million	15,372 Added 77.55%	35,194 $2.59 Million
Q4 2021 Dec 09, 2024	SELL	$134.56 - $217.97 $2.45 Million - $3.97 Million	-18,206 Reduced 47.88%	19,822 $2.84 Million
Q3 2021 Dec 09, 2024	BUY	$177.8 - $270.58 $5.64 Million - $8.58 Million	31,708 Added 501.71%	38,028 $7.88 Million
Q2 2021 Dec 09, 2024	BUY	$121.0 - $257.67 $764,720 - $1.63 Million	6,320 New	6,320 $1.34 Million

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $666M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Swedbank Ab, based on Form 13F filings with the SEC.

Stay updated on Swedbank Ab with notifications on news.